| Attributes | Values |
|---|
| rdf:type
| |
| description
| - article scientifique publié en 2004 (fr)
- artículu científicu espublizáu en 2004 (ast)
- vědecký článek publikovaný v roce 2004 (cs)
- 2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած (hyw)
- 2004 թվականի փետրվարին հրատարակված գիտական հոդված (hy)
- наукова стаття, опублікована в лютому 2004 (uk)
- vedecký článok (publikovaný 2004/02/13) (sk)
- wetenschappelijk artikel (gepubliceerd op 2004/02/13) (nl)
- مقالة علمية (نشرت في 13-2-2004) (ar)
- scientific article (publication date: 13 February 2004) (en)
- im Februar 2004 veröffentlichter wissenschaftlicher Artikel (de)
|
| publication date
| |
| publication date
| |
| language of work or name
| |
| language of work or name
| |
| author name string
| |
| author name string
| - Zoltán Papp
- Jouko Levijoki
- Petri Kaheinen
- Heimo Haikala
- István Edes
- Szabolcs Szilágyi
|
| rdfs:label
| - The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig (en)
- The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig (nl)
- The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig (ast)
|
| skos:prefLabel
| - The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig (en)
- The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig (nl)
- The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig (ast)
|
| name
| - The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig (en)
- The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig (nl)
- The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig (ast)
|
| author
| |
| author
| |
| title
| |
| title
| - The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig (en)
|
| page(s)
| |
| page(s)
| |
| instance of
| |
| instance of
| |
| main subject
| |
| main subject
| |
| PubMed ID
| |
| PubMed ID
| |
| PubMed ID
| |
| published in
| |
| published in
| |
| issue
| |
| volume
| |
| issue
| |
| volume
| |
| DOI
| |
| DOI
| |
| DOI
| - 10.1016/J.EJPHAR.2003.12.005
|
| ResearchGate publication ID
| |
| ResearchGate publication ID
| |
| is about
of | |
| is cites work
of | - Positive inotropic effect of levosimendan is correlated to its stereoselective Ca2+-sensitizing effect but not to stereoselective phosphodiesterase inhibition
- A structural and functional perspective into the mechanism of Ca2+-sensitizers that target the cardiac troponin complex
- Structure and function of cardiac troponin C (TNNC1): Implications for heart failure, cardiomyopathies, and troponin modulating drugs
- Effects of the calcium sensitizer OR-1896, a metabolite of levosimendan, on post-infarct heart failure and cardiac remodelling in diabetic Goto-Kakizaki rats
- Clinical pharmacology of levosimendan
- Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats.
- Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs.
- Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus
- Targeting the sarcomere to correct muscle function
- Cardiac myosin activation part 1: from concept to clinic
- The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles
- Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart
- Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials.
- Effects of Ca2+ -sensitizers in permeabilized cardiac myocytes from donor and end-stage failing human hearts
- Levosimendan enhances force generation of diaphragm muscle from patients with chronic obstructive pulmonary disease
- Cardiovascular parameters in anaesthetized guinea pigs: a safety pharmacology screening model
- Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.
- Probing the mechanism of cardiovascular drugs using a covalent levosimendan analog
- Levosimendan improves calcium sensitivity of diaphragm muscle fibres from a rat model of heart failure
- The utility of levosimendan in the treatment of heart failure
- The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the rat
- Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription.
- Levosimendan attenuates multiple organ injury and improves survival in peritonitis-induced septic shock: studies in a rat model
- Effect of levosimendan on the contractility of muscle fibers from nemaline myopathy patients with mutations in the nebulin gene.
- Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations
- Calcium sensitizers: What have we learned over the last 25 years?
- An emerging role for calcium sensitisation in the treatment of heart failure
- Pharmacological preconditioning by levosimendan is mediated by inducible nitric oxide synthase and mitochondrial KATP channel activation in the in vivo anesthetized rabbit heart model.
- The inotropic effect of the active metabolite of levosimendan, OR-1896, is mediated through inhibition of PDE3 in rat ventricular myocardium
- Structures reveal details of small molecule binding to cardiac troponin
- Levosimendan and its metabolite OR-1896 elicit KATP channel-dependent dilation in resistance arteries in vivo
- The peroxynitrite evoked contractile depression can be partially reversed by antioxidants in human cardiomyocytes
- Epidemiology, Pathophysiology and Contemporary Management of Cardiogenic Shock - A position statement from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
- Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use
- In vitro effects of levosimendan on muscle of malignant hyperthermia susceptible and non-susceptible swine
- The clinical effects of levosimendan are not attenuated by sulfonylureas.
|
| is cites work
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)